Cargando…

Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study

BACKGROUND: The management of breakthrough pain (BTP) in cancer patients is a challenge. It is clinically useful to evaluate the effectiveness of rapid-onset opioid at a starting dose in proportional to the background opioid regimen. This open-label, multicenter, noncomparative study aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yen, Tsung-Yu, Chiou, Jeng-Fong, Chiang, Wei-Yong, Su, Wen-Hao, Huang, Ming-Yuan, Hu, Ming-Hung, Wu, Shen-Chi, Lai, Yuen-Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078661/ https://www.ncbi.nlm.nih.gov/pubmed/30045291 http://dx.doi.org/10.1097/MD.0000000000011593

Ejemplares similares

Considerations in selecting rapid-onset opioids for the management of breakthrough pain
por: Smith, Howard S
Publicado: (2013)

A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain
por: Smith, Howard
Publicado: (2012)

Considerations in selecting rapid-onset opioids for the management of breakthrough pain
por: Perelman, Michael, et al.
Publicado: (2013)

Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
por: Bossi, Paolo, et al.
Publicado: (2022)

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
por: Mercadante, S, et al.
Publicado: (2007)

Quality Improvement in Acute Ischemic Stroke Care in Taiwan: The Breakthrough Collaborative in Stroke
por: Hsieh, Fang-I, et al.
Publicado: (2016)

Breakthrough Pain: The Importance of Baseline Analgesic Regimen with Opioids
por: Zampi, Maddalena, et al.
Publicado: (2012)

Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study
por: Hoffman, Kent, et al.
Publicado: (2017)

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea
por: Ahn, Yo Han, et al.
Publicado: (2018)

A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain
por: Setnik, Beatrice, et al.
Publicado: (2015)

A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients
por: Jung, Ji Yoon, et al.
Publicado: (2022)

Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study
por: Cuomo, Arturo, et al.
Publicado: (2020)

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation
por: Brenner, Darren M., et al.
Publicado: (2019)

Proportions of Proinflammatory Monocytes Are Important Predictors of Mortality Risk in Hemodialysis Patients
por: Jeng, Yachung, et al.
Publicado: (2017)

Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation
por: Takigawa, Chizuko, et al.
Publicado: (2015)

Effect of Relative Humidity on Adsorption Breakthrough of CO(2) on Activated Carbon Fibers
por: Chiang, Yu-Chun, et al.
Publicado: (2017)

A New Labeling Approach for Proportional Electromyographic Control
por: Hagengruber, Annette, et al.
Publicado: (2022)

Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain
por: Devulder, J., et al.
Publicado: (2009)

Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study
por: Gao, Lehong, et al.
Publicado: (2023)

Differential Pharmacological Actions of Methadone and Buprenorphine in Human Embryonic Kidney 293 Cells Coexpressing Human μ-Opioid and Opioid Receptor-Like 1 Receptors
por: Lee, Cynthia Wei-Sheng, et al.
Publicado: (2011)

Effectiveness and safety of morinidazole in the treatment of pelvic inflammatory disease: A multicenter, prospective, open-label phase IV trial
por: Zhou, Ting, et al.
Publicado: (2022)

The effect of transdermal opioid use on breakthrough opioid and sedative prescribing for rural patients with chronic pain in Northwest Tasmania: a longitudinal study
por: Henshaw, John, et al.
Publicado: (2013)

The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
por: Samolsky Dekel, Boaz Gedaliahu, et al.
Publicado: (2021)

Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study
por: Lee, Jong Eun, et al.
Publicado: (2022)

The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain
por: Mercadante, Sebastiano, et al.
Publicado: (2021)

Proportion of opioid use due to compensated workers' compensation claims in Manitoba, Canada
por: Kraut, Allen, et al.
Publicado: (2015)

ECAP‐Controlled Closed‐Loop Spinal Cord Stimulation Efficacy and Opioid Reduction Over 24‐Months: Final Results of the Prospective, Multicenter, Open‐Label Avalon Study
por: Brooker, Charles, et al.
Publicado: (2021)

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
por: Deng, Li-Juan, et al.
Publicado: (2023)

Breakthrough!
por: KURNIT, Paul
Publicado: (2010)

A multicenter, open-label, phase III study of Abcertin in Gaucher disease
por: Lee, Beom Hee, et al.
Publicado: (2017)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease
por: Kainuma, Mosaburo, et al.
Publicado: (2022)

Measles Resurgence in Europe: An Open Breakthrough in the Field of Vaccine-Preventable Diseases
por: De Francesco, Maria Antonia
Publicado: (2023)

Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment
por: Chu, Yu-De, et al.
Publicado: (2023)

First add‐on perampanel for focal‐onset seizures: An open‐label, prospective study
por: Kim, Ji Hyun, et al.
Publicado: (2019)

An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial
por: Koga, Tomohiro, et al.
Publicado: (2020)

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
por: Chen, Cheng-Pin, et al.
Publicado: (2020)

A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
por: Hsieh, Ming-Hong, et al.
Publicado: (2010)

Effect of prehospital notification on acute stroke care: a multicenter study
por: Hsieh, Ming-Ju, et al.
Publicado: (2016)

Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects
por: Jeng, Bennie H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_592rivebcihd203oc4cjvempbi